Canadian health regulators will not hesitate to change the terms of the AstraZeneca coronavirus vaccine license if additional safety issues emerge, Health Minister Patty Hajdu said.
Hajdu was grilled by the official opposition's health critic, Michelle Rempel Garner, about Canada's first reported case of blood clotting following inoculation with the AstraZenaca vaccine.
"All vaccines approved for use in Canada undergo routine and scrutinous attention. All adverse effects are reported through Health Canada and Health Canada monitors that data closely and will not hesitate to change its licensing for use in Canada should there be any risk to Canadians," Hajdu said during a Question Period session on Tuesday.
The first reported case of blood clotting will be included in Health Canada's study of the link between the AstraZeneca vaccine and the deadly side effect, the federal department said in a statement earlier on Tuesday.
Health Canada has paused inoculating Canadians under the age of 55 with the AstraZeneca vaccine following a recommendation from Canada's National Advisory Committee on Immunizations (NACI).
Canadian health regulators have also issued a disclaimer regarding blood clots that may potentially form in individuals who receive an AstraZeneca shot, but have not officially listed it as an official side effect.
Concerns about vaccine side effects began in mid-March, following dozens of reports of blood clotting after inoculations, prompting several nearly 20 countries to halt the rollout of the AstraZeneca vaccine.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU